AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. - Wikidata - awgldk - TriplyDB

AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa.

AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa.

http://www.wikidata.org/entity/Q35092388

about

Genetic manipulation for inherited neurodegenerative diseases: myth or reality?Immunology of AAV-Mediated Gene Transfer in the Eye A comprehensive review of retinal gene therapy Ablation of C/EBP homologous protein does not protect T17M RHO mice from retinal degeneration Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery Targeting the Nrf2 Signaling Pathway in the Retina With a Gene-Delivered Secretable and Cell-Penetrating Peptide The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.Gene augmentation for adRP mutations in RHO.Expression of wild-type Rp1 protein in Rp1 knock-in mice rescues the retinal degeneration phenotype Rhodopsin gene expression determines rod outer segment size and rod cell resistance to a dominant-negative neurodegeneration mutant Vector platforms for gene therapy of inherited retinopathies.Efficient mutagenesis of the rhodopsin gene in rod photoreceptor neurons in mice.Genetically engineered pig models for human diseases.Mislocalization and degradation of human P23H-rhodopsin-GFP in a knockin mouse model of retinitis pigmentosa A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation.Erythropoietin Slows Photoreceptor Cell Death in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa.ER stress is involved in T17M rhodopsin-induced retinal degeneration.Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.Preliminary study on electrophysiological changes after cellular autograft in age-related macular degeneration Retinal Gene Therapy: Current Progress and Future Prospects.Nanoparticle-mediated rhodopsin cDNA but not intron-containing DNA delivery causes transgene silencing in a rhodopsin knockout model.AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.Rhodopsin targeted transcriptional silencing by DNA-binding.Proteasome overload is a common stress factor in multiple forms of inherited retinal degeneration.Assessment of visual function and retinal structure following acute light exposure in the light sensitive T4R rhodopsin mutant dog Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration Gene-based therapies for dominantly inherited retinopathies.Gene therapy in animal models of autosomal dominant retinitis pigmentosa Gene therapy for retinal disease Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid.CRB1: one gene, many phenotypes.Insights gained from gene therapy in animal models of retGC1 deficiency.Gene therapies for inherited retinal disorders.Leber congenital amaurosis caused by mutations in GUCY2D.The Status of RPE65 Gene Therapy Trials: Safety and Efficacy Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward.Gene delivery to the retina: from mouse to man.Pattern of retinal morphological and functional decay in a light-inducible, rhodopsin mutant mouse.Gene therapy to treat inherited and complex retinal degenerative diseases Assessing the correlation between mutant rhodopsin stability and the severity of retinitis pigmentosa

P2860

Q26752831-97405709-7B81-47DF-836D-1BB16DA94441 Q27023474-2F0511F9-2426-4D8F-8C5E-197A9DBFA92B Q27023914-3EE578ED-C701-4EF7-AAE1-16BE0912D109 Q27321032-A6CF7175-CD28-4EE3-9FD1-86D169288019 Q27325842-C043B406-E25A-47AB-844B-7930107FF3B3 Q28394174-39DE97AB-52B6-4DB2-8C23-6FA66D2A2477 Q30525669-3CB007BC-DFCC-4CC8-991A-464AFD8FDC04 Q34083185-49892FB8-1EFE-4CB3-AA89-50761A17B78E Q34395630-A4387B91-FB72-4414-AF02-EB6BFDF04A93 Q34490664-D91C1E34-3CCF-4FF6-9317-4B2F483204E9 Q34561531-526BFB5D-5835-4E28-83C4-9FB3D611E123 Q35153494-0E91B7BE-3A86-4ECD-8AD3-5E76E27CE956 Q35700104-B0097FC3-F65E-42C2-B9B5-F12707E63F01 Q35925204-9BDB5574-5787-4991-B999-25F4C4BC64A9 Q36009841-DD6D3DEF-4BE0-4217-BD58-A8CD54159F28 Q36051639-1C541CB5-239B-4206-88C3-0C88255D7444 Q36077630-038178A3-C932-4080-A969-56EF446281E8 Q36147481-3B955795-89F7-4610-B0ED-60EB0D2E9195 Q36151822-482372E3-02F6-4514-948C-5F3EE99593CB Q36306263-0DD87016-B39A-43D7-B04B-A1F3316A5E0B Q36570955-8D7AD8F5-10DB-4545-A7FD-61C7920F068B Q36635482-0494143E-7F2F-40FE-AAF0-0FC1BDFBC3B1 Q36723420-38823C1A-2CF6-4266-8AF6-5EBC4D1DFEFC Q36932207-175C6701-5180-4927-B313-15BF1AA02E42 Q37217166-E7135551-AD45-4243-950F-5FDE5665C102 Q37407667-45A7D0E8-227E-43AE-ABDD-EFA4BB35E456 Q37956945-2EFE9AD0-847E-4A50-9A26-624683862A05 Q38053151-2738ED77-C00B-48ED-BB4A-85E948535B75 Q38073020-EA6690BC-DD03-4307-A53F-524D64A5EC06 Q38100572-B6B948FD-6A8F-4D0A-B183-3D9AC92270F7 Q38153736-BA48570F-F9F4-4ECD-BC7F-05BEAD8E824F Q38214595-1DBEC1A3-37D6-4B57-9F8F-550D1674474C Q38221905-3232D173-3D70-406B-86F1-26EE1928FDE5 Q38254324-B846CB74-E9AA-41EE-A729-B144804ADF75 Q38337392-BF2EB342-E831-4D37-BDFA-2737B2C1AF88 Q38732888-A083B279-05BE-47BE-B8F3-DFBBD9423722 Q40820678-78A37992-9FBB-467D-963E-461AFCF72809 Q41051547-BC568FB7-6615-492A-8D1E-BDC5EE30BF01 Q41855514-BA4B35B1-24D8-4D37-AEB9-68B04A624863 Q41941697-EFD8357C-6AAE-47DD-B460-9D450B5D89C6

P2860

AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa.

http://www.wikidata.org/entity/Q35092388

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@ast

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@en

type

label

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@ast

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@en

prefLabel

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@ast

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@en

P1433

Q35092388-47527B60-D08F-477E-9B95-F0D3B1704307

P1476

Q35092388-675ECD82-3F3E-4C2D-B6BF-68660DB26DF3

P2093

Q35092388-0E765E83-3717-4B36-9CEF-2E0264F1244D

Q35092388-339FA5A0-188E-451F-AD2F-D92AAC386212

Q35092388-3674028B-6EDC-408A-93A5-43A6D8F600C9

Q35092388-560908D5-AD32-41BD-8F08-89DBD8192DEF

Q35092388-7BDCE659-3523-4D81-A97A-1B718E16BE35

Q35092388-84514C2E-D691-4519-AF60-BFCFADD13D77

Q35092388-989D5B25-E81E-4548-BF88-8F87A0115E0E

P2860

Q35092388-039261B2-7AF6-4399-A621-321FFFC0DE41

Q35092388-042CAE8F-48C7-41BE-A8CA-5D80013882A8

Q35092388-04CC91F1-085C-4F7C-B157-A93B0C3DAF36

Q35092388-07330BE7-4D56-4ADA-8FA6-E593824DAC52

Q35092388-08CD27DA-DE60-42AF-A5F8-C3B1849443E0

Q35092388-117E8212-8AC4-4662-94E9-AB1760023EDE

Q35092388-18923825-172B-42B7-9295-5A194FED1174

Q35092388-1A6D1399-257E-4110-8112-0D054E21B203

Q35092388-1B50E20B-82C4-437C-80F7-DBF150482DD2

Q35092388-25567A5C-6CB2-4F4D-818C-E1852D879F56

P304

Q35092388-B27625A6-E34B-4229-B7B5-A23A59B7D247

P31

Q35092388-AE5D911D-FCD0-4D01-90EF-F84BBA23F786

P356

Q35092388-056473BB-9065-4DB4-9A28-A420D06EA640

P433

Q35092388-A703B6DF-D23A-4855-AAFA-B794C99C2AB3

P478

Q35092388-779DE76A-CBF7-4FB3-AC43-0E1FA2798467

P577

Q35092388-077EBB22-50B8-4E6B-AB10-E91E61424943

P5875

Q35092388-57950507-3D46-464B-9438-E3D221FF70CA

P698

Q35092388-54B117DC-24D2-482F-BEC8-53C995D485AE

P932

Q35092388-F57D3634-9472-4E64-AB9E-25DFFBFF9D26

P356

P1433

Human Gene Therapy

P1476

AAV delivery of wild-type rhod ...... dominant retinitis pigmentosa.

@en

P2093

Alfred S Lewin

http://www.w3.org/2001/XMLSchema#string

Alison Schwein

http://www.w3.org/2001/XMLSchema#string

Arseniy E Shabashvili

http://www.w3.org/2001/XMLSchema#string

Haoyu Mao

http://www.w3.org/2001/XMLSchema#string

Marina S Gorbatyuk

http://www.w3.org/2001/XMLSchema#string

Thomas James

http://www.w3.org/2001/XMLSchema#string

William W Hauswirth

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy

On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention

Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration

Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa

Effect of gene therapy on visual function in Leber's congenital amaurosis

IRE1 signaling affects cell fate during the unfolded protein response

Retinitis pigmentosa

Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina.

P304

567-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2010.140

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49653172

http://www.w3.org/2001/XMLSchema#string

P698

21126223

http://www.w3.org/2001/XMLSchema#string

P932

3131806

http://www.w3.org/2001/XMLSchema#string